ADAM17-overexpressing breast cancer cells selectively targeted by antibody-toxin conjugates (Q47197303)

11 January 2018

title

ADAM17-overexpressing breast cancer cells selectively targeted by antibody-toxin conjugates (English)

1 reference

11 January 2018

1 reference

7

1 reference

11 January 2018

Stefan Rose-John

object named as

Stefan Rose-John

12

0 references

author name string

Ahmad Trad

1

1 reference

11 January 2018

Hinrich P Hansen

2

1 reference

11 January 2018

Mohammad Shomali

3

1 reference

11 January 2018

Matthias Peipp

4

1 reference

11 January 2018

Katja Klausz

5

1 reference

11 January 2018

Nina Hedemann

6

1 reference

11 January 2018

André Mauermann

8

1 reference

11 January 2018

Christine Desel

9

1 reference

11 January 2018

Inken Lorenzen

10

1 reference

11 January 2018

Hilmar Lemke

11

1 reference

11 January 2018

Joachim Grötzinger

13

1 reference

11 January 2018

publication date

1 September 2012

1 reference

11 January 2018

Cancer Immunology, Immunotherapy

published in

1 reference

11 January 2018

volume

62

1 reference

11 January 2018

issue

3

1 reference

11 January 2018

page(s)

411-421

1 reference

11 January 2018

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

ADAM17: a molecular switch to control inflammation and tissue regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

Expression of ADAMs ("a disintegrin and metalloprotease") in the human lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

ADAM17 promotes glioma cell malignant phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

ADAM-17: the enzyme that does it all.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

ADAM12 and ADAM17 gene expression in laser-capture microdissected and non-microdissected breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

ADAM-17 predicts adverse outcome in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

Human kappa light chain targeted Pseudomonas exotoxin A--identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

Development of sandwich ELISA for detection and quantification of human and murine a disintegrin and metalloproteinase17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

Natural killer cells are crucial for the efficacy of Icon (factor VII/human IgG1 Fc) immunotherapy in human tongue cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

Elimination of HIV-1 infection by treatment with a doxorubicin-conjugated anti-envelope antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

Increased expression of tumor necrosis factor-alpha converting enzyme and tumor necrosis factor-alpha in peripheral blood mononuclear cells in patients with advanced congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

Activated tumour necrosis factor-alpha shedding process is associated with in-hospital complication in patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

ADAM17 as a therapeutic target in multiple diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

Migration of growth factor-stimulated epithelial and endothelial cells depends on EGFR transactivation by ADAM17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

BR96-DOX immunoconjugate targeting of chemotherapy in brain tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

Doxorubicin-conjugated anti-midkine monoclonal antibody as a potential anti-tumor drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

Immunotoxin treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1346-X

10.1007/S00262-012-1346-X

21 January 2018

Identifiers

DOI

1 reference

11 January 2018

1 reference

11 January 2018